Immune System Diseases clinical trials

The registry lists 427 studies for Immune System Diseases across more than 10 countries. 86 are recruiting or about to start. 55 of them are mainly about Immune System Diseases (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 156 narrower conditions too, such as HIV Infections: 49,265 studies, 8,954 open.

Get an email when these change. Save the Immune System Diseases studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 219
Recruiting: 74
Terminated: 40
Active, not recruiting: 33
Status unknown: 30
Withdrawn: 13

Phase

Phase 2: 131
Phase 1: 102
Phase 3: 66
Phase 4: 14
Early Phase 1: 1

Where

United States: 221
Canada: 58
Spain: 53
United Kingdom: 49
Germany: 46
France: 45

Who runs them

National Center for Research Resources (NCRR) (25) · National Institute of Allergy and Infectious Diseases (NIAID) (14) · UNC Lineberger Comprehensive Cancer Center (8) · Pfizer (8) · AO GENERIUM (7) · AstraZeneca (5) · Novartis Pharmaceuticals (5) · Kadmon, a Sanofi Company (5)

What is being tested here

Drugs under test in Immune System Diseases studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
IMG-007	2	0	4
Tilrekimig	2	2	2
Mezagitamab	2	2	2
JADE101	2	1	2
Cenerimod	1	3	3
Bezuclastinib	1	0	2
Fludarabine	1	0	2
Tezepelumab	1	0	2
Litifilimab	1	1	1
Urinastatin	1	0	1

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 2 open · Antimetabolites 1 open · Alkylating agents 10 · JAK inhibitors 7 · Immune checkpoint inhibitors 3

Coming up

15phase 3 studies under way

27studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Dec 2026A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus · Phase 3 · Viatris Innovation GmbH
Jan 2027Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) · Phase 3 · AstraZeneca
Mar 2027A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus · Phase 3 · Viatris Innovation GmbH
Dec 2026A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study · OriCell Therapeutics Co., Ltd.
Dec 2026HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis · Center for International Blood and Marrow Transplant Research
Dec 2026Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers · University of Southern California
Feb 2027Project Khanya: Peer-Delivered Intervention to Improve HIV Medication Adherence and Substance Use in South Africa · University of Maryland, College Park
Feb 2027A Study of HL40626S Tablets in Healthy Adults · HighsLab Therapeutics Inc.
Mar 2027A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma · Kelonia Therapeutics, Inc.
Mar 2027A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition · Joseph Oved

Who these studies take

Of the 74 Immune System Diseases studies recruiting now, 40 (54%) set no upper age limit and 22 (30%) stop at 75 or younger. 22 (30%) take children under 18. 3 (4%) are for women only and 0 (0%) for men only; 18 (24%) take healthy volunteers.

Recruiting studies that take each age, of 74
Age	Women	Men
10	17 (23%)	17 (23%)
18	66 (89%)	63 (85%)
30	67 (91%)	64 (86%)
40	69 (93%)	66 (89%)
50	68 (92%)	66 (89%)
65	61 (82%)	61 (82%)
75	56 (76%)	56 (76%)
85	51 (69%)	51 (69%)

Across all 427 studies, recruiting or not: 48% stop at 75 or younger and 33% at 65; 31% take children; 4% are for women only and 2% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Immune System Diseases studies take

Of 41 phase 2 interventional studies under Immune System Diseases, half reached primary completion within 46 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	29 mo5–69 · 39 studies	11 mo4–32 · 25 studies	—
Phase 1/2	71 mo31–111 · 22 studies	—	—
Phase 2	46 mo34–144 · 41 studies	—	—
Phase 3	48 mo19–65 · 32 studies	—	—
Interventional, no phase	18 mo8–49 · 33 studies	—	—
Observational	48 mo17–… · 47 studies	—	48 mo16–… · 45 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 427. Browse all 427 → or search them.